Vir Biotechnology, Inc. (VIR) reported a quarterly loss of $0.31 per share for the period ending December 2025, outperforming the Zacks Consensus Estimate of a loss of $0.42 and improving from a loss of $0.76 per share a year earlier. The company’s revenues reached $64.07 million, significantly surpassing the consensus estimate by 243.23% and up from $12.37 million year-over-year.
This earnings announcement marks a +26.89% surprise in EPS, but Vir has only exceeded EPS expectations just once over the past four quarters. The current consensus for the next quarter anticipates a loss of $0.60 on revenues of $2.41 million, while the fiscal year outlook shows a projected loss of $2.94 on revenues of $13.28 million.
Since the beginning of the year, Vir Biotechnology shares have gained approximately 25.4%, contrasting with a 0.9% rise in the S&P 500. The company is currently assigned a Zacks Rank of #3 (Hold), indicating expected performance in line with the market.
